Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

308.75DKK
2:42pm BST
Change (% chg)

kr.1.95 (+0.64%)
Prev Close
kr.306.80
Open
kr.310.00
Day's High
kr.310.10
Day's Low
kr.304.05
Volume
1,410,381
Avg. Vol
3,074,659
52-wk High
kr.354.80
52-wk Low
kr.260.20

Latest Key Developments (Source: Significant Developments)

Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 Billion
Friday, 4 May 2018 

May 4 (Reuters) - Novo Nordisk A/S ::AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION.APPOINTED NORDEA DANMARK, FILIAL AF NORDEA BANK AB (PUBL) AS LEAD MANAGER TO EXECUTE PROGRAMME INDEPENDENTLY.  Full Article

Novo Nordisk: FDA Approves Update to Tresiba Label to Include Devote data
Monday, 26 Mar 2018 

March 26 (Reuters) - Novo Nordisk ::U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED AN UPDATE TO US PRESCRIBING INFORMATION FOR TRESIBA (INSULIN DEGLUDEC) TO INCLUDE DATA FROM THE DEVOTE TRIAL​.‍FOLLOWING INTERACTIONS WITH FDA, NOVO NORDISK HAS WITHDRAWN APPLICATIONS RELATED TO DATA FROM SWITCH TRIALS​.‍"VERY PLEASED THAT FDA HAS APPROVED UPDATED LABEL FOR TRESIBA AS ONLY BASAL INSULIN TO BE LABELLED WITH A LOWER RATE OF SEVERE HYPOGLYCAEMIA COMPARED TO INSULIN GLARGINE U100," SAYS CSO MADS KROGSGAARD THOMSEN​.  Full Article

Novo Nordisk Says Ozempic Approved In Japan For The Treatment Of Type 2 Diabetes
Friday, 23 Mar 2018 

March 23 (Reuters) - NOVO NORDISK A/S SAYS::OZEMPIC APPROVED IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES.EXPECTS TO LAUNCH OZEMPIC® IN JAPAN IN THE COMING MONTHS, WHEN REIMBURSEMENT HAS BEEN OBTAINED..  Full Article

Novo Nordisk Says Semaglutide Injection Is Now Available Across Canada
Monday, 5 Mar 2018 

March 5 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK - OZEMPIC(®) (SEMAGLUTIDE INJECTION) IS NOW AVAILABLE ACROSS CANADA.  Full Article

Novo Nordisk Submits Haemophilia Drug For Approval in the U.S and the EU
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Novo Nordisk ::FILES FOR REGULATORY APPROVAL OF LONG-ACTING FACTOR VIII (N8-GP) IN THE U.S. AND THE EU FOR TREATMENT OF HAEMOPHILIA A.SAYS IN ‍TRIAL, ADULTS TREATED PROPHYLACTICALLY WITH N8-GP EVERY FOURTH DAY EXPERIENCED A MEDIAN ANNUALISED BLEEDING RATE OF 1.3 EPISODES COMPARED TO 30.9 EPISODES FOR PEOPLE TREATED ON-DEMAND.PAEDIATRIC PARTICIPANTS EXPERIENCED A MEDIAN ANNUALISED BLEEDING RATE OF 1.95 EPISODES WHEN ADMINISTERED TWICE WEEKLY.HAEMOSTATIC RESPONSE WAS REPORTED AS 'EXCELLENT' OR 'GOOD' IN 43 OUT OF THE 45 PERFORMED SURGERIES​ IN SURGERY TRIAL."BASED ON THE RESULTS FROM THE GLOBAL PATHFINDER CLINICAL TRIAL PROGRAMME, WE BELIEVE N8-GP CAN REDUCE THE BURDEN OF TREATMENT BY DECREASING THE NUMBER OF INTRAVENOUS INFUSIONS WHILE ACHIEVING THE BENEFITS IN TERMS OF EFFICACY AND SAFETY FOR PEOPLE WITH HAEMOPHILIA A," CHIEF SCIENCE OFFICER MADS KROGSGAARD THOMSEN SAID..  Full Article

Novo Nordisk Proposes Two New Board Members
Friday, 23 Feb 2018 

Feb 23 (Reuters) - NOVO NORDISK ::SAYS ‍BOARD OF DIRECTORS PROPOSES ELECTION OF ANDREAS FIBIG AND MARTIN MACKAY AS NEW MEMBERS OF BOARD OF DIRECTORS AT ANNUAL GENERAL MEETING MARCH 22.FIBIG IS CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF INTERNATIONAL FLAVORS & FRAGRANCES.MACKAY IS FORMER EXECUTIVE VICE PRESIDENT AND GLOBAL HEAD OF RESEARCH AND DEVELOPMENT AT ALEXION PHARMACEUTICALS, INC., US, AND HAS ALSO BEEN HEAD OF RESEARCH & DEVELOPMENT IN BOTH ASTRAZENECA PLC. AND PFIZER​.  Full Article

Novo Nordisk Says Successfully Completes First Trial For Oral Semaglutide
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - NOVO NORDISK SAYS::SUCCESSFULLY COMPLETES THE FIRST PHASE 3A TRIAL, PIONEER 1, WITH ORAL SEMAGLUTIDE.‍TRIAL ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL PRINCIPLE BY DEMONSTRATING SIGNIFICANT AND SUPERIOR IMPROVEMENTS IN HBA (LONG-TERM BLOOD SUGAR) FOR ALL THREE DOSES OF ORAL SEMAGLUTIDE COMPARED TO PLACEBO​.14 MG DOSE OF ORAL SEMAGLUTIDE DEMONSTRATED SIGNIFICANT AND SUPERIOR WEIGHT LOSS VERSUS PLACEBO, WEIGHT LOSS WAS OBSERVED FOR 7 MG AND 3 MG DOSES BUT DID NOT REACH STATISTICAL SIGNIFICANCE​.‍WE ARE VERY ENCOURAGED BY RESULTS OF PIONEER 1 TRIAL, WHICH CONFIRM UNPRECEDENTED ORAL EFFICACY OF SEMAGLUTIDE THAT WAS REPORTED IN PHASE 2 CLINICAL TRIAL IN TYPE 2 DIABETES​.‍WE LOOK FORWARD TO PROVIDING DATA FROM REMAINING NINE PIONEER TRIALS THROUGHOUT THIS YEAR AND AN EXPECTED REGULATORY SUBMISSION IN 2019​.  Full Article

Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU
Friday, 9 Feb 2018 

Feb 9 (Reuters) - NOVO NORDISK ::OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​.SAYS ‍OZEMPIC HAS BEEN APPROVED IN EU FOR USE IN A MULTI-DOSE PEN, HOWEVER, NOVO INTENDS TO SUBMIT A VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) SEEKING APPROVAL OF AN UPDATED OZEMPIC PEN OFFERING.OZEMPIC WAS APPROVED BY THE U.S. FDA ON 5 DECEMBER 2017 nL1N1O51MY.  Full Article

Novo Nordisk Launches Rebinyn In The United States For People With Hemophilia B
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK LAUNCHES REBINYN® IN THE UNITED STATES FOR PEOPLE WITH HEMOPHILIA B.  Full Article

Novo Nordisk Announces Availability Of New Diabetes Medications At Pharmacies Across U.S.
Monday, 5 Feb 2018 

Feb 5 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK - ANNOUNCED AVAILABILITY OF NEW DIABETES MEDICATIONS, OZEMPIC INJECTION 0.5 MG OR 1 MG AND FIASP 100 UNITS/ML AT PHARMACIES ACROSS U.S..  Full Article

Novo Nordisk says haemophilia drug data support clinical profile

May 21 A head-to-head trial showed that people with haemophilia B who received Novo Nordisk's Refixia achieved greater total factor IX exposure than those treated with recombinant factor IX-Fc Fusion Protein, the Danish company said on Monday.